NAC Supplementation Shows Promise in Reducing Preterm Birth Complications

A recent study led by Küster and colleagues suggests that antenatal N-acetylcysteine (NAC) supplementation could help reduce complications in babies born preterm. The findings highlight its potential as a therapeutic option for women at risk of early labour. Researchers now call for further exploration of this low-cost intervention alongside existing treatments. The trial focused on pregnant women facing imminent preterm birth. When administered in controlled doses, NAC did not shorten gestation or harm fetal growth. Instead, it reduced acute neonatal complications and lowered maternal infections and inflammation.

NAC works by boosting glutathione levels, which helps cells neutralise harmful free radicals. It also dampens pro-inflammatory signals by modulating NF-κB pathways. Timing appears key—giving NAC in the critical period before preterm birth maximises its protective effects. The study also combined biochemical tests with clinical outcomes to assess NAC’s impact. This approach strengthened the case for its use. However, the researchers stress that larger, multi-centre trials are needed to confirm these benefits across different populations. Beyond preterm birth, the results raise questions about oxidative stress in other pregnancy complications. Conditions like preeclampsia and fetal growth restriction may also benefit from antioxidant therapies. The team suggests integrating NAC with standard treatments, such as corticosteroids and tocolytics, for better perinatal outcomes.

The findings support NAC as a promising addition to preterm birth management. Its ability to reduce neonatal complications and inflammation without side effects makes it a viable option. Further research will determine its broader role in improving pregnancy outcomes.